Y Intercept Hong Kong Ltd Purchases New Shares in Intellia Therapeutics, Inc. $NTLA

Y Intercept Hong Kong Ltd acquired a new position in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) in the 1st quarter, Holdings Channel.com reports. The fund acquired 141,081 shares of the company’s stock, valued at approximately $1,809,000.

A number of other hedge funds have also bought and sold shares of NTLA. Elevation Point Wealth Partners LLC raised its stake in shares of Intellia Therapeutics by 93.8% in the first quarter. Elevation Point Wealth Partners LLC now owns 167,807 shares of the company’s stock valued at $2,151,000 after acquiring an additional 81,234 shares during the period. Pictet Asset Management Holding SA raised its position in Intellia Therapeutics by 47.2% in the 1st quarter. Pictet Asset Management Holding SA now owns 16,933 shares of the company’s stock worth $217,000 after purchasing an additional 5,429 shares during the period. Lewis Asset Management LLC lifted its stake in Intellia Therapeutics by 38.5% in the first quarter. Lewis Asset Management LLC now owns 19,770 shares of the company’s stock worth $253,000 after purchasing an additional 5,500 shares during the last quarter. SG Americas Securities LLC boosted its position in shares of Intellia Therapeutics by 22.6% during the first quarter. SG Americas Securities LLC now owns 89,688 shares of the company’s stock valued at $1,150,000 after buying an additional 16,545 shares during the period. Finally, Rockefeller Capital Management L.P. grew its stake in shares of Intellia Therapeutics by 1.7% during the fourth quarter. Rockefeller Capital Management L.P. now owns 140,218 shares of the company’s stock valued at $1,261,000 after buying an additional 2,277 shares during the last quarter. Institutional investors own 88.77% of the company’s stock.

Insiders Place Their Bets

In other Intellia Therapeutics news, CAO Michael P. Dube sold 2,641 shares of the stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $16.78, for a total transaction of $44,315.98. Following the sale, the chief accounting officer owned 66,886 shares of the company’s stock, valued at approximately $1,122,347.08. This trade represents a 3.80% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Edward J. Dulac III sold 4,677 shares of Intellia Therapeutics stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $18.00, for a total value of $84,186.00. Following the completion of the transaction, the executive vice president owned 156,286 shares in the company, valued at $2,813,148. This represents a 2.91% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 3.50% of the stock is owned by corporate insiders.

Intellia Therapeutics Stock Performance

Shares of NTLA opened at $15.44 on Friday. The company has a 50 day moving average price of $14.37 and a 200-day moving average price of $13.29. Intellia Therapeutics, Inc. has a fifty-two week low of $7.95 and a fifty-two week high of $28.25. The stock has a market capitalization of $2.16 billion, a PE ratio of -4.36 and a beta of 1.77.

Intellia Therapeutics (NASDAQ:NTLA) last issued its quarterly earnings data on Monday, May 11th. The company reported ($0.81) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.92) by $0.11. The company had revenue of $15.05 million for the quarter, compared to analyst estimates of $13.81 million. Intellia Therapeutics had a negative net margin of 597.04% and a negative return on equity of 57.47%. During the same period last year, the company posted ($1.10) earnings per share. Equities research analysts forecast that Intellia Therapeutics, Inc. will post -3.18 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Intellia Therapeutics in a research note on Tuesday, April 21st. Citizens Jmp reaffirmed a “market outperform” rating and issued a $30.00 price objective on shares of Intellia Therapeutics in a research report on Monday, June 15th. Citigroup reiterated a “market outperform” rating on shares of Intellia Therapeutics in a research note on Monday, June 15th. New Street Research set a $25.00 target price on Intellia Therapeutics in a research report on Monday, June 15th. Finally, Chardan Capital boosted their target price on shares of Intellia Therapeutics from $27.00 to $30.00 and gave the company a “buy” rating in a research note on Monday, April 27th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, ten have issued a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $20.46.

Intellia Therapeutics Profile

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.